Research Portfolio
Adore challenges conventional research paradigms by adopting a multidisciplinary approach that transcends traditional disease-specific frameworks. Rather than studying diseases solely within the confines of a single discipline—such as neurology or oncology—Adore fosters a broader, integrative perspective that encourages groundbreaking ideas beyond traditional scientific boundaries.
Currently, six out of seven focus groups are actively managing projects, each overseeing between one and three initiatives. Project funding ranges from €700,000 to €1.85 million, with additional investments in the pipeline.
Our funding strategy is designed to support both strong research infrastructure and cutting-edge innovation. Looking ahead, we will place greater emphasis on a “high-risk, low-cost” approach to accelerate implementation, foster breakthrough ideas, and maximize impact. At the same time, “low-risk, high-cost” proposals with strong innovation potential and high expected impact remain welcome.
Below, you will find an overview of previously funded projects and their details. Proposals that are currently under review are also higlighted.
| Project name | Focus group | Brief description | Time-line | Budget |
|---|---|---|---|---|
| CRISPR – Cut to the Chase | Proteomics & Genomics | This project aims to accelerate both cancer and brain research using cutting-edge CRISPR technology. | May 2024 – May 2029 | €748.000 |
| EV-PREDICT | Proteomics & Genomics | The aim of this project is to further improve the use and the interpretation of cerebrospinal fluid (CSF) biomarkers as predictors of disease pathogenesis and to use that information to develop precision medicine for heterogeneous brain disorders. | November 2024 – November 2028 | €1.220.000 |
| TRANSVISION | Proteomics & Genomics | This project aims to establish a novel approach for multi-cell type disease modeling and set-up CRISPR screening for new therapeutic targets involved in neuron-tumor and glia-tumor interactions | April 2025 – April 2029 | €1.837.000 |
| BioDORA | Biobanking & Biomarkers | The overall objective of this project is to develop BioDORA as an Amsterdam infrastructure facilitating access to, and mining of clinical variables and biomaterials of patient cohorts and age-matched healthy individuals. | November 2024 – November 2029 | €988.000 |
| Gen-BioDORA | Biobanking & Biomarkers | With the GEN-BioDORA project we centralize storage of virtual patient materials (liquids and tissues) for Adore research use and reuse with back-ups. | September 2024 – September 2028 | €988.000 |
| Crossing barriers | Imaging | This proof-of-concept study will assess whether we can measure the brain delivery and distribution of TILs and mAbs in patients with Positron Emission Tomography (PET) imaging. | TBD | €1.052.000 |
| Crossing barriers | Immuno- & Cellular therapy | The overall aim of this project is to define how the brain microenvironment controls immune cell infiltration into the CNS during health (healthy age continuum, incl 100-plus cohort) and in the neurological disorders multiple sclerosis (MS) and Alzheimer’s disease(AD) and the oncological disorder glioblastoma (GBM) and brain metastatic lung tumours and melanoma | TBD | €1.099.000 |
| NICITA | Immuno- & Cellular therapy | The aim of this project is to characterize common and distinct immunological pathomechanisms in immune-mediated neuroinflammatory diseases (imNDs) and immune-related adverse events (irAEs) of cancer immunotherapy. | September 2024 – September 2028 | €1.000.000 |
| Immunemonitoring Unit | Immuno- & Cellular therapy | The primary objective of this project is to create an infrastructure to allow the integration of immune monitoring in clinical trials for cancer and neurological diseases at Adore. | January 2025 – January 2026 | €1.252.000 |
| Cell2sample | Biocomputation | The goal of this project is to establish a comprehensive computational framework that integrates diverse omics data types, including (single-cell) RNA/DNA sequencing and spatially resolved molecular data, available from both public sources and ongoing projects of Adore researchers. | TBD: 4 years | €688.000 |
| Micro to macro (M2M) | Biocomputation | The goal of this project is to develop computational techniques that bridge the microscale and macroscale in neurological and oncological diseases. | TBD: 4 years | €688.000 |
| Building2Understanding | Biocomputation | The ultimate aim of this project is to improve predictive models based on cell type-specific genetic properties | TBD: 4 years | €688.000 |
| CAVIR | Immuno- & Cellular therapy | Adore supports this project that aims to understand the applicability of CAR-T technology in the context of neurodegenerative diseases | – | €20.000 |
| Clinical Research Support | Clinical Research | Adore Clinical Research Support (ACRS) is to strengthen the pipeline of therapeutic development in both Oncology and Neurology, by sharing resources, leveraging on each other’s expertise, and investing in staff that allows cross-discipline activities. | tbd | €1.185.000 |